Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

By Morgan Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 723-728

Springer Publishing Company

Access to resources Recommend Favorite

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma

By Millward Michael   Joshua Anthony   Kefford Rick   Aamdal Steinar   Thomson Damien   Hersey Peter   Toner Guy   Lynch Kevin  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 253-256

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

By Ernst D   Eisenhauer Elizabeth   Wainman Nancy   Davis Mary   Lohmann Reinhard   Baetz Tara   Belanger Karl   Smylie Michael  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 569-575

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

By Burdette-Radoux Susan   Tozer Richard   Lohmann Reinhard   Quirt Ian   Ernst D.   Walsh Wendy   Wainman Nancy   Colevas A.   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 315-322

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite